Skip to main content
. 2017 Nov 20;8(62):106017–106025. doi: 10.18632/oncotarget.22522

Figure 2. Baculovirus survival in human serum.

Figure 2

Recombinant BmNPV showed stronger resistance to complement inactivation in human serum than recombinant AcMNPV.